Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Cross Below 200 Day Moving Average – Should You Sell?

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $31.10 and traded as low as $28.21. Lakefront Biotherapeutics American Depositary Shares shares last traded at $28.37, with a volume of 125,293 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Royal Bank Of Canada increased their price objective on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th. Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Up 0.7%

The firm has a market cap of $1.87 billion, a PE ratio of -20.12 and a beta of 0.26. The stock has a 50-day simple moving average of $28.17 and a two-hundred day simple moving average of $31.10.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The company had revenue of $1.06 billion during the quarter. Research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. State of Wyoming purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter worth about $28,000. Van ECK Associates Corp grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 750 shares during the last quarter. Arax Advisory Partners grew its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,778 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter worth about $134,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter worth about $211,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.